A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.

Inclusion Criteria:

• Mild to moderate, primary open angle glaucoma
• Characteristics consistent with mild to moderate glaucoma
• Use of 1 - 4 ocular hypotensive medications at the Screening exam and meets the IOP (intraocular pressure) criteria
• Visually significant cataract

Exclusion Criteria:

Any of the following prior treatments for glaucoma (study eye):

• Laser Trabeculoplasty
• Endocyclophotocoagulation (ECP) or Micropulse laser
• iStent or iStent Inject
• Hydrus Microstent
• Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma drainage device/valve.
• Prior canaloplasty (ab-interno and ab-externo)
• Prior goniotomy, or trabeculotomy (ab-interno or ab-externo)
• Suprachoroidal stent (e.g., Cypass, iStent Supra, XEN, MINIject)
• Concurrent IOP-lowering procedure other than use of the iTrackTM Advance canaloplasty device at the time of surgery (e.g., ECP, CPC, etc.)
• Previous treatment with iTrack (Note: permitted if fellow eye only was treated)
• Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma